Abstract

Early reperfusion of the infarct related coronary artery is essential for the preservation of myocardial tissue and improve clinical outcome. The establishment of pharmacological and mechanical reperfusion treatment was a major improvement in the management of patients with myocardial infarction. However, this therapy is often complicated by reperfusion injury including ventricular arrhythmias, myocardial stunning and micro-vascular dysfunction, in addition to significant cardiomyocyte death. The most important factors which contribute to the reperfusion injury are an overproduction of reactive oxygen species, intracellular calcium overload and inflammatory cell infiltration. Some of these mechanisms may be interrelated. From considerations of their nature, an attractive hypothesis has been that some or several of these harmful effects may be counteracted by pharmacological interventions. This hypothesis has mainly been studied in the experimental setting.Objective – in this review, various pharmacological interventions to treat myocardial reperfusion injury including the antioxidant flavonols, glucose – insulin – potassium therapy, adenosine, melatonin, phosphocreatine and cyclosporin A etc.Conclusions. The processes involved in reperfusion injury might provide targets for improved outcomes after myocardial infarction but that aim has thus far not been met in the clinic. By studying new molecules in different experimental settings and protocols, insight has been gained about important factors for possible future clinical applications of drugs with cardioprotective properties.

Highlights

  • A – концепция и дизайн исследования; B – сбор данных; C – анализ и интерпретация данных; D – написание статьи; E – редактирование статьи; F – окончательное утверждение статьи

  • The processes involved in reperfusion injury might provide targets for improved outcomes after myocardial infarction but that aim has far not been met in the clinic

  • Ряд РКИ направлен именно на предотвращение И/Р повреждения миокарда при проведении реперфузии у пациентов с острым инфарктом миокарда (ОИМ) с элевацией сегмента ST, многие результаты были в значительной степени разочаровывающими

Read more

Summary

Conclusions

The processes involved in reperfusion injury might provide targets for improved outcomes after myocardial infarction but that aim has far not been met in the clinic. By studying new molecules in different experimental settings and protocols, insight has been gained about important factors for possible future clinical applications of drugs with cardioprotective properties. Реперфузия миокарда у пациентов с острым инфарктом миокарда (ОИМ) с элевацией сегмента ST на ЕКГ – наиболее эффективное вмешательство для ограничения размера инфаркта миокарда (ИМ), сохранения систолической функции левого желудочка (ЛЖ) и снижения частоты сердечной недостаточности (СН). Лежащих в основе И/Р повреждения привело к изучению в экспериментальных и клинических исследованиях перспективных фармакотерапевтических стратегий для снижения тяжести И/Р повреждения миокарда. В дальнейшем в более крупных исследованиях одни препараты подтвердили свою эффективность, другие – нет

Цель работы
Патофизиологические механизмы реперфузионного повреждения

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.